{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:02:14Z","timestamp":1794938534889,"version":"4.9.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ygyno.2025.07.026","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T16:02:11Z","timestamp":1754323331000},"page":"161-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer"],"prefix":"10.1016","volume":"200","author":[{"given":"Giorgio","family":"Bogani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Chiantera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierandrea","family":"De Iaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Vizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Scollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Petrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violante","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vizzielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2025.07.026_bb0005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.07.026_bb0010","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2025.07.026_bb0015","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1245\/s10434-009-0357-0","article-title":"Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis","volume":"16","author":"Harter","year":"2009","journal-title":"Ann. Surg. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2025.07.026_bb0020","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of Cytoreductive surgery for relapsed ovarian Cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2025.07.026_bb0025","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian Cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ygyno.2025.07.026_bb0030","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.07.026_bb0035","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after Hyperthermic intraperitoneal chemotherapy and primary or interval Cytoreductive surgery in ovarian Cancer: a randomized clinical trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg."},{"key":"10.1016\/j.ygyno.2025.07.026_bb0040","article-title":"Hyperthermic intraperitoneal chemotherapy in platinum-sensitive recurrent ovarian Cancer: a randomized trial on survival evaluation (HORSE; MITO-18)","author":"Fagotti","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2025.07.026_bb0045","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S1470-2045(24)00531-X","article-title":"Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial","volume":"25","author":"Classe","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.07.026_bb0050","doi-asserted-by":"crossref","unstructured":"Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann. Surg. Oncol. 2015 May;22(5):1570\u20135. doi:10.1245\/s10434-014-4157-9. Epub 2014 Nov 13. PMID: 25391263.","DOI":"10.1245\/s10434-014-4157-9"},{"issue":"2","key":"10.1016\/j.ygyno.2025.07.026_bb0055","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3390\/curroncol31020048","article-title":"Paclitaxel as HIPEC-drug after surgical Cytoreduction for ovarian peritoneal metastases: a randomized phase III clinical trial (HIPECOVA)","volume":"31","author":"Villarejo Campos","year":"2024","journal-title":"Curr. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.07.026_bb0060","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian Cancer: a phase 3 clinical trial","volume":"29","author":"Antonio","year":"2022","journal-title":"Ann. Surg. Oncol."},{"issue":"372","key":"10.1016\/j.ygyno.2025.07.026_bb0065","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"29","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.ygyno.2025.07.026_bb0070","doi-asserted-by":"crossref","first-page":"e2013940","DOI":"10.1001\/jamanetworkopen.2020.13940","article-title":"Evaluation of Cytoreductive surgery with or without Hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian Cancer","volume":"3","author":"Lei","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"20","key":"10.1016\/j.ygyno.2025.07.026_bb0075","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.3390\/cancers16203500","article-title":"HIPEC as up-front treatment in locally advanced ovarian Cancer","volume":"16","author":"Karanikas","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2025.07.026_bb0080","first-page":"100518","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: is BRCA mutational status making the difference?","volume":"31","author":"Ghirardi","year":"2022","journal-title":"Cancer Treat Res Commun."},{"key":"10.1016\/j.ygyno.2025.07.026_bb0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2022.12.021","article-title":"Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01)","volume":"170","author":"Kim","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"49","key":"10.1016\/j.ygyno.2025.07.026_bb0090","doi-asserted-by":"crossref","first-page":"e20223135","DOI":"10.1590\/0100-6991e-20223135","article-title":"A phase 2 trial of short-course Hyperthermic IntraPeritoneal chemotherapy (HIPEC) at interval cytoreductive surgery (iCRS) for advanced ovarian cancer","volume":"28","author":"Batista","year":"2022","journal-title":"Rev. Col. Bras. Cir."},{"issue":"8","key":"10.1016\/j.ygyno.2025.07.026_bb0095","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/ijc.34124","article-title":"Effect of HIPEC according to HRD\/BRCAwt genomic profile in stage III ovarian cancer: results from the phase III OVHIPEC trial","volume":"151","author":"Koole","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2025.07.026_bb0100","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1245\/s10434-024-15042-0","article-title":"Expanding the use of HIPEC in ovarian Cancer at time of interval Debulking surgery to FIGO stage IV and after 6 cycles of neoadjuvant chemotherapy: a prospective analysis on perioperative and oncologic outcomes","volume":"31","author":"Ghirardi","year":"2024","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.07.026_bb0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3802\/jgo.2015.26.1.54","article-title":"Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study","volume":"26","author":"Coccolini","year":"2015","journal-title":"J. Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.07.026_bb0110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00404-014-3252-2","article-title":"Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey","volume":"290","author":"Grosso","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"issue":"2","key":"10.1016\/j.ygyno.2025.07.026_bb0115","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/bjc.2014.602","article-title":"Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer","volume":"112","author":"Ansaloni","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2025.07.026_bb0120","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijc.29011","article-title":"HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer","volume":"136","author":"Zivanovic","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.07.026_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/jso.27913","article-title":"Review of options to traditional HIPEC for prevention and treatment of peritoneal metastases","author":"Sugarbaker","year":"2024","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2025.07.026_bb0130","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.suronc.2020.09.019","article-title":"HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study","volume":"35","author":"Sugarbaker","year":"2020","journal-title":"Surg. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2025.07.026_bb0135","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.3390\/jcm12227012","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC): new approaches and controversies on the treatment of advanced epithelial ovarian Cancer-systematic review and Meta-analysis","volume":"12","author":"Della Corte","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ygyno.2025.07.026_bb0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ygyno.2023.12.019","article-title":"Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: a multicenter phase I trial","volume":"181","author":"Wu","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.07.026_bb0145","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3802\/jgo.2024.35.e1","article-title":"A phase I dose-finding trial of hyperthermic intraperitoneal docetaxel combined with cisplatin in patients with advanced-stage ovarian cancer","volume":"35","author":"You","year":"2024","journal-title":"J. Gynecol. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2025.07.026_bb0150","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1158\/1078-0432.CCR-24-0507","article-title":"Intraperitoneal Nivolumab after Debulking surgery and Hyperthermic intraperitoneal chemotherapy in advanced ovarian Cancer: a phase I study with expansion cohort","volume":"30","author":"Corbaux","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2025.07.026_bb0155","series-title":"NIH National Library of Medicine","year":"2025"},{"issue":"4","key":"10.1016\/j.ygyno.2025.07.026_bb0160","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/med.22027","article-title":"Fluorescent imaging probes for in vivo ovarian cancer targeted detection and surgery","volume":"44","author":"Solidoro","year":"2024","journal-title":"Med. Res. Rev."},{"issue":"11","key":"10.1016\/j.ygyno.2025.07.026_bb0165","doi-asserted-by":"crossref","first-page":"e2446325","DOI":"10.1001\/jamanetworkopen.2024.46325","article-title":"Laparoscopic Cytoreduction after neoadjuvant chemotherapy in high-grade epithelial ovarian Cancer: a LANCE randomized clinical trial","volume":"7","author":"Rauh-Hain","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"10.1016\/j.ygyno.2025.07.026_bb0170","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1007\/s00464-022-09589-w","article-title":"Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a prospective clinical trial and comparative analysis","volume":"37","author":"Cho","year":"2023","journal-title":"Surg. Endosc."},{"key":"10.1016\/j.ygyno.2025.07.026_bb0175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2023.02.003","article-title":"Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial","volume":"171","author":"Praiss","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.07.026_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/jso.27885","article-title":"Review of 2022 PSOGI\/RENAPE consensus on HIPEC","author":"Kusamura","year":"2024","journal-title":"J. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.07.026_bb0185","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.3802\/jgo.2022.33.e54","article-title":"Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)","volume":"33","author":"Kim","year":"2022","journal-title":"J. Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2025.07.026_bb0190","doi-asserted-by":"crossref","first-page":"110120","DOI":"10.1016\/j.ejso.2025.110120","article-title":"Enhancing surgical precision in ovarian cancer with FR\u03b1-fluorescence-guided surgery","volume":"51","author":"Ferrari","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2025.07.026_bb0195","article-title":"Enhancing surgical education through artificial intelligence in the era of digital surgery","volume":"2","author":"Aurello","year":"2025","journal-title":"Am. Surg."},{"issue":"6","key":"10.1016\/j.ygyno.2025.07.026_bb0200","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.17676","article-title":"Interval Cytoreductive surgery and cisplatin- or paclitaxel-based HIPEC for advanced ovarian Cancer","volume":"8","author":"Gonz\u00e1lez S\u00e1nchez","year":"2025","journal-title":"JAMA Netw. Open"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825009369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825009369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T19:44:06Z","timestamp":1758915846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825009369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"alternative-id":["S0090825825009369"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.07.026","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}